source
- Industry and rare disease groups call for more transparency in FDA voucher pilotThe pharmaceutical industry and rare‑disease advocacy groups have voiced concerns about the Commissioner's National Priority Voucher pilot program. Stakeholders say the program lacks transparency…
- ADA conference preview spotlights newer GLP-1 drugs, research funding cuts and a protestElizabeth Cooney reports from the American Diabetes Association annual meeting in New Orleans, introducing the first of three STAT "ADA in 30 Seconds" newsletters. She notes the warm weather outsid…